News

The protocols for the two studies 102 and 030 were reviewed and prospectively approved by the FDA under its special protocol assessment (SPA) procedure. Both studies achieved their

In this study, the efficacy of multiple doses of 600mg of MEM 1414 on the allergen-induced asthmatic response in steroid free subjects with mild allergic asthma will be

In conjunction with this transaction, EMD Serono Canada, an affiliate of Merck KGaA, has assumed control of Oncothyreon’s facility in Edmonton, Canada, which is primarily utilized for the

The company is planning to treat amyotrophic lateral sclerosis (ALS) patients through spinal injections of its stem cells via its patented human neural stem cell technology. Neuralstem expects

ACT III is a randomized open-label, two-arm, Phase IIb/III trial comparing CDX-110 combined with temozolomide to temozolomide alone in patients with newly diagnosed glioblastoma multiforme (GBM). Only the

An open-label Phase Ib clinical trial is expected to enroll up to 42 patients with locally advanced or metastatic solid tumors in order to evaluate the safety and efficacy of

The Drs Hans Schreuder scar treatment product is expected to contain soya extract, which is known to even out skin tone and texture. The cream is also expected to

This Phase I trial is designed to evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for Pelizaeus-Merzbacher disease (PMD). Currently, there are no approved

The randomized, double-blind, placebo-controlled, single-center, single ascending dose study is expected to evaluate the safety and pharmacokinetic profile of SPL-017. A total of 74 healthy adult male subjects are expected to be